This implies that MSP binding effect on the AKT pathway is kinase domain independent, or that pancreatic cancer cells utilize compensatory mechanisms to activate AKT in the setting of RON kinase inhibition. This evidence concerns the gene AKT1 and pancreatic neoplasm.